



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/56	A1	(11) International Publication Number: WO 97/37662 (43) International Publication Date: 16 October 1997 (16.10.97)
(21) International Application Number: PCT/US97/05849 (22) International Filing Date: 10 April 1997 (10.04.97) (30) Priority Data: 60/015,042 11 April 1996 (11.04.96) US 60/018,985 4 June 1996 (04.06.96) US (71)(72) Applicant and Inventor: LORIA, Roger, M. [US/US]; 3219 Brook Road, Richmond, VA 23227 (US). (74) Agent: HENDRICKS, Glenna; Hendricks & Associates, P.O. Box 2509, Fairfax, VA 22031 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: 5-ANDROSTENE 3 β ,17 α DIOL AS AN INHIBITOR OF TUMOR GROWTH (57) Abstract The instant invention provides means of accelerating cell aging and programmed cell death in tumor cells by administration of 3 β ,17 α androstenediol (α AED) or its ethers or esters.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Title: 5-ANDROSTENE 3 β ,17 α DIOL AS AN INHIBITOR OF TUMOR GROWTH

5 Background of the Invention:

Field of the Invention:

10 This invention relates to the field of pharmaceuticals for tumor-inhibitory effects. The 5-androstene 3 β ,17 α diol (α AED), its esters and ethers, are taught herein to achieve tumor-inhibiting effect.

Description of Related Art:

15 Mifepristone (RU486) is used as a progesterone receptor antagonist (See U.S. Patent 4,386,085, which is incorporated herein by reference in its entirety) and has been shown to have use both as an abortifacient and has been found useful for treating steroid-dependent breast cancer.

20 Flutamide, which has been disclosed in U.S. patent 3,847,988 (which is incorporated herein by reference in its entirety) is an antiandrogen that has been used to treat prostatic cancer, usually in conjunction with estrogen.

25 U.S. Patent 2,521,586 to Levy, et al., teaches production of the 17-monobenzoate ester of androstene diol. No use of the 5-androstene 3 β , 17 α diol (α AED) is taught therein.

30 Peat, in U.S. Patent 4,628,052 teaches a genus which might, arguably, within the scope of the genus, encompass the α AED. However, all examples and all named compounds require a keto group. Hence, it is reasonable to conclude that the α AED is not intended therein.

35 Tindall, in U.S. Patent 2,845,381 teaches cosmetic compositions containing the α AED. No medicinal compositions appropriate for internal use or medicinal uses are suggested therein.

U.S. Patent 4,882,322 to Johnson, et al. Teaches

substituted 5-androstene 3 β ,17 β diol to regulate or inhibit the conversion of androgens to estrogens. The α AED is not taught therein.

Swartz, et al., in U. S. Patent 4,898,694 teaches a very large group of compounds which encompass substituted androstenediols. However, Schwartz does not suggest the α AED nor the esters and ethers claimed herein for any purpose.


Loria, in U.S. Patents 5,206,008, 5,277,907, 5,3876,583, 5,461,042 and 5,478,566 teaches that the 5-androstene 3 β ,17 β diol (β AED) and 5,-androstene 3 β ,7 β ,17 β triol (AET) enhance immune response, and also are useful for counteracting the untoward effects of irradiation and chemotherapy, and buffer the anti-proliferative effects of hydrocortisone. None of these patents teaches or suggests use of α AED. As taught therein, the β AED is most effective if administered in such a manner that it contacts tissue of ectodermal origin.

Summary of the Invention:

The instant invention provides a means of accelerating cell aging and programed cell death in tumor cells. The practice of the invention involves administration of 3 β ,17 α androstenetriol (which may be referred to in this application as either 17 α AED or simply α AED) and esters and ethers thereof.

Description of the Invention:

The instant invention relates to the use of 5-androstene 3 β ,17 α diol (herein referred to as α AED or 17 α AED), its esters and ethers, to inhibit growth and accelerate cell aging, induce apoptosis and death of tumor cells as a means of treating malignancies. The active agents of the invention may also be used as contraceptives and abortifacients. The active agents are of the structure:



wherein R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR₂, wherein R₂ is H; alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or phenyl. Any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized.

It has been found that these active agents, when administered as described herein, inhibit cell growth. The αAED is administered in sufficient dosages to provide a blood concentration of from 5 to 10,000 nM when given systemically. A more preferred blood or tissue fluid concentration is in the range of 10 to 10,000 nM. The dosage will vary with the type of cell to be inhibited. The method of administration will depend on the location of the target cells. Such means as parenteral or oral administration are also appropriate. The αAED may also be administered by applicator or in a spray to tissue during surgery. Compositions containing the active agents taught herein may be administered vaginally or rectally either by instillation of a liquid composition or on supports such as sponges.

Other preferred methods of administration include buccal, sublingual, nasal or endotracheal routes. Sprays or mists may be useful for such administration. Furthermore, sprays may be useful for administration to the operative area during surgery.

For example, sprays may be used to contact the peritoneal cavity or the thoracic cavity during surgery.

Compositions of the invention may also be administered to the intestinal mucosa by oral or rectal routes. Suppositories, solutions for use as retention enemas and creams or jellies are appropriate means for use in rectal administration.

Compositions of the invention may also be applied to the vaginal mucosa using creams, jellies suppositories or douching solutions. The compositions may be in the form of prophylactic vaginal preparations or may be used in lubricants on condoms. Jellies and creams may also be administered by application in a cervical diaphragm which, when in place, will provide for prolonged contact with the cervix.

For purposes of administration into an orifice of the body, the compositions of the invention may be administered via a flexible tube into the target site. As indicated previously, the compositions containing α AED may be administered as a douche or retention enema. Other target sites include the bladder, uterus, trachea, nasopharynx, sinus or (via the nasal passage) the pituitary.

The carrier system used in a given instance will depend on the mode of administration. The active agents are lipophilic compounds. Solvents and carriers for lipophilic steroids known in the art are appropriate for use in the compositions containing α AED or the esters and ethers of α AED. Examples of such carriers are glycols such as polypropylene glycol, polyethylene glycol, ethanol, DMSO and cyclodextrins (especially the amorphous cyclodextrins). Cyclodextrins will pass through the buccal mucosa into the circulation easily. This method is particularly appropriate for administration as a means of avoiding intravenous administration while bypassing the liver. Other vehicles that should be considered include fatty acid esters of polyoxyethylene sorbital (Tweens) or sorbitan (Spans) for preparation of emulsions.

The compositions taught herein may be used to treat most neoplasms, including for, for example, use in treatment of neoplasms, including those of the blood-forming organs, the liver, pancreas, thyroid, adrenals, pituitary, ovaries, testicles, breast, central nervous system (including brain, spinal column), bone, connective tissue, lungs, liver, the gastro-intestinal system, connective tissue, uterus, mucous membranes, mouth and tongue, the lining of the peritoneum, the lymphatics and sensory organs.

Materials and Methods:

The β AED, 17 beta-oestradiol and tamoxifen were obtained from Sigma Chemical Company (St. Louis, Missouri). The α AED and Flutamide were obtained from Steriloid, Inc. (Walton, New Hampshire) and Schering Corporation (Kenilworth, New Jersey), respectively. All steroids except β AED were dissolved in ethanol. β AED was dissolved in DMSO:ETHOL (1:1 v/v). Stock solutions were filtered and kept at 4°C. For testing, stock solutions were diluted in media immediately before use. The final concentration of vehicle was always $\leq 0.2\%$ in all samples, and this concentration had no significant cytotoxic effect on the human breast cell cancer cell line designated ZR-75-1 (American Type Culture Collection) as determined by trypan blue exclusion.

The ZR-75-1 cell line (passage 89) was obtained from the American Type Culture Collection (Rockville, Maryland). The cells were cultured in RPMI-1640 medium containing 10% heat-inactivated fetal calf serum, 200 μ M L-glutamine, 10 mM HEPES, 1.5 U/ml penicillin, and 1.5 μ g/ml streptomycin in 5% CO₂ at 37°C. The cells were passaged twice weekly.

Cell Growth for testing:

Cells were first seeded at initial density of 1×10^5 cells per ml in quadruplicates in 24 multi-well flat bottom plates (Costar). Cells were then allowed to adhere and grow in phenol red-free RPMI 64 media supplemented with 10 % heat-inactivated fetal calf serum (FCS), 200 μ M L-glutamine, 10 mM HEPES, 2.5

U/ml penicillin and 2.5 μ g/ml streptomycin in 5% CO₂ at 37°C. After 48 hours, four wells were sacrificed and counted to determine plating efficiency. In the remaining wells, medium was removed by aspiration and cells in each well were exposed to the media containing the specified steroid. The controls containing only medium or medium with vehicle were also prepared. In all samples, medium was changed every 48 hours. At the pre-established time-point. Cells were removed by trypsinization and washed. Cell number and viability were determined by trypan blue exclusion using a hemocytometer. Parallel cultures were also run to determine cell proliferation.

Cell Proliferation Assays:

For cell proliferation assays, cell suspensions were prepared by trypsinization of cells from cultures prepared in accord with methods described above. Cell viability was determined by trypan blue exclusion. The cells were then seeded in flat-bottom 96-well microtiter plates at a density of 2×10^3 cells/well and were allowed to rest for 48 hours in order to adhere. Non-adherent dead cells were removed by aspiration. Cells were then grown in media without phenol red. Some of the media contained supplements as indicated above. The active agents or vehicle control were added to the media. The cells were then grown for six days. Media was changed on the samples every 48 hours. On day 6, cells were pulsed with 1 μ Ci [³J]-thymidine for the last 6 hours of incubation before harvesting onto glass filter using a HPD cell harvester (Cambridge Technology, Watertown, Massachusetts) and counted on a KLB scintillation counter.

Initial tests were carried out to determine the optimal (maximal) dose of α AED required to inhibit growth of the ZR-75-1 cells in in vitro as determined by tritiated thymidine incorporation. It was found that treatment of ZR-75-1 cells with α AED at doses ranging from 3.13 nM to 50 nM lead to a biphasic effect on the growth of ZR-71-1 cells when compared

to vehicle control after 6 days. The α AED stimulated proliferation of ZR-75-1 cells at concentrations between 6.25 and 12.5 nM ($P < 0.01$) when compared with the vehicle control. At concentration of 25 nM or greater, the α AED significantly inhibited the growth of ZR-75-1 cells, and this anti-proliferative effect occurred in a dose and time-dependent manner at half-maximal (50 nM) and maximal dose (100 nM) levels. To ensure that inhibition was not due to cytotoxicity, cell count and viability were assessed by trypan blue exclusion. The addition of the 17 α AED was not toxic to the cells. As opposed to α AED, the β AED alone at 100 nM concentrations did not have any antiproliferative effect on the growth of the ZR-75-1 cells.

Example 1:

ZR-75-1 cells (2×10^3) were treated as described above over a six day period with differing concentrations of α AED or with vehicle-only cultures. The medium was changed every 48 hours. Cells were pulsed with ^3H -thymidine for the last six hours of incubation.

Results showed increasing proliferation at 6.25 nM with decreasing cell proliferation at 25 nM and marked decrease at concentrations of 50 nM concentrations.

Example 2:

Cells were treated as in Example 1, except that in some samples a combination of 17 α AED and β AED were used. The concentration of the α AED varied while the concentration of the β AED in the samples containing the combination of agents remained constant at 2.5 nM. Cells were pulsed with ^3H -thymidine for the last six hours.

The proliferation of cells in cultures containing α AED in the presence of β AED showed decreased proliferation at all concentrations of α AED.

Example 3:

Effects of α AED on growth of ZR-75-1 cells in the presence of estradiol was studied. Cells treated with increasing

concentration of α AED in the presence or absence of 1 nM concentration of estradiol over a 6 day period were studied. Cells were treated with increasing concentration of α AED in the presence if 1 nM concentration of estradiol over a 6 day period, with medium changed every 48 hours. Cells were pulsed with ^3H -thymidine for the last six hours of incubation. At higher doses of α AED the α AED suppressed proliferation even in the presence of estradiol. Hence, estradiol can not effectively overcome the antiproliferative activity of α AED on this human breast cancer cell line.

Example 4:

Effects of α AED on growth of ZR-75-1 cells in the presence of Flutamide, an antiandrogen, were studied using the process of Example 3 except that estradiol was replaced with Flutamide. At concentrations of ≥ 6.25 nM concentrations of α AED, the antiproliferative effects were greatly enhanced in the presence of Flutamide. Hence, Flutamide appears to act synergistically with α AED to produce antiproliferative effects. Hence, the administration of α AED with antiandrogens, especially in treating estrogen-dependent malignancies such as breast cancer, should be considered particularly advantageous treatment option.

Example 5:

Example 5 was again studied in the presence of RU486. Again, it was shown that at effective concentrations it was possible to lower dosage of RU486 in the presence of effective amounts of .1 μM concentrations of α AED with 0.5 μM concentration of RU486 there was synergistic action to decrease proliferation of cells. This synergism was shown to be even greater at RU486 concentrations of 1 μM . This combination of active agents would be especially useful for treatment of tumors which are dependent on estrogen or progesterone

Example 6:

Preparation for instillation:

	Ingredient	%w/w
	α AED	0.01%
5	polypropylene glycol	13.0 %
	Water	86.5%

Example 7:

Preparation for intravenous injection:

	Ingredient	Amount
10	α AED	1 mg.
	Ethanol	5 ml.
	Phosphate buffered saline	Add to 1000 ml.

Example 8:

Effect of α AED on growth of lymphoid neoplasm (P388D1 cells obtained from the American Type Culture Collection) in the presence of RU486 at concentration of 0.5 μ M and 1.0 μ M was studied in accord with the methods described above. It was found that the use of α AED in combination with RU486 resulted in increased effectiveness over use of one agent.

Example 9:

Effects of α AED at doses of 50 nM and 100 nM doses on murine macrophage myeloma cells (RAW 264.7, obtained from the American Type Culture Collection) was studied. At both 50 nM and 100 nM levels there was significant inhibition of proliferation.

Example 10:

Preparation for instillation into the bladder for treatment of bladder cancer:

	Ingredient	Amount
	α AED	10 mg
	DMSO	100 ml
35	half-normal saline	900 ml.

Example 11:

Water, 100 ml, is mixed with 7 g. β -hydroxypropyl cyclodextrin and 1 mg α AED. Fill ampules with the solution and sterilize. This preparation may be added to solutions for administration to the mucosa, for oral administration, or for parenteral administration.

Example 12:

The cyclodextrin/ α AED preparation is prepared as above. The material is freeze-dried and placed in sterile ampules. The resulting powder may be placed in vials. The contents of the vials may then be snorted into the nasal cavity. It is also appropriate to dissolve the contents of the vials and place in solution for intravenous or topical application, including for infusion into a wound site. It may also be applied by spraying or sponging into the operative site such as the abdominal or thoracic cavity.

Example 13:

The preparation of Example 12 is diluted with 100 ml water. The preparation is sprayed into the abdominal cavity during and after removal of a colon malignancy.

α AED may be delivered to or through the skin by any means, including subcutaneous or intradermal injection or topical application. One means of topical application is the use of skin patches impregnated with the active agent. This means of delivery is advantageous since it is non-invasive and easily administered by relatively unskilled care providers.

Example 14:

Capsules of a formulation of α AED for oral administration is prepared by mixing 2 mg. α AED, 15 mg. Starch and 5 mg. Magnesium stearate. The capsules are administered twice a day to achieve a daily dosage of 1-50 mg./da.

The compositions of the invention may be administered intrathecally either at the spinal level or into the cisterna magna.

When α AED, its esters or ethers are administered orally,

it is necessary that the active agents be protected from destruction and absorption in the upper gastro-intestinal tract. The active agents are most effective when the period of exposure to the mucosa of the intestinal tract is increased. Hence use of capsules containing the active agents in formulations that effect slow release in the intestine are appropriate.

The active agents may also be used in veterinary medicine for treatment of animals suffering from tumors. For purposes of such treatment, the α AED may be added to the chow of the animals.

The sterile solutions may be administered to the lung either by bronchoscopic means or by mist which may be under pressure.

Patched for administration of α AED may be formulated as adhesive patches containing the active agent. For example, the patch may be a discoid in which a pressure-sensitive silicone adhesive matrix containing the active agent may be covered with a non-permeable backing. The discoid may either contain the active agent in the adhesive or may be attached to a support made of material such as polyurethane foam or gauze that will hold the active agent. When patches are used in treating animals, the area must be shaved or plucked. In all instances, the area to which the patch is applied should be cleaned carefully before application.

Example 15:

A patch composed of trilaminate of an adhesive matrix sandwiched between a non-permeable backing and a protective covering layer is prepared in the following manner:

To a pressure-sensitive silicone adhesive composition BIOPSA™ q7-2920 (Dow Corning Corporation, Midland, Michigan, U.S.A.) in cyclohexane (50% w/v) is added sufficient α AED to provide a .5% α AED composition. The adhesive is applied to a polyester film to provide in successive layers about 2 mg. Of active agent per cm². Patches should be covered with a

protective layer which will be removed before application.


Patches may be prepared containing permeation enhancers such as cyclodextrin, butylated hydroxyanisole, or butylated hydroxytoluene.

5 The active agents may be administered to the mucosa of oral, pharyngeal or nasal cavity by tablet or lozenge.

10 The antiproliferative agents taught herein may be used in conjunction with other active agents such as vinca alkaloids, nucleic acid inhibitors, platinum agents, interleukin-2, interferons, alkylating agents, antimetabolites, corticosteroids, DNA intercalating agents, anthracyclines and ureas. Examples of specific agents, in addition to those exemplified herein, include hydroxyurea, 5-fluorouracil, anthramycin, asparaginase, bleomycin, dactinomycin, dacabazine, 15 cytarabine, busulfan, thiotepa, lomustine, mechlorethamine, cyclophosphamide, melphalan, mechlorethamine, chlorambucil, carmustine, 6-thioguanine, methotrexate, etc.

WHAT WE CLAIM IS:

1. A composition of matter comprising a tumor proliferation-inhibiting effective amount of α AED or an ester or ether thereof of the formula:




wherein R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR_2 , wherein R_2 is H; alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or phenyl, and any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, in a form appropriate for oral administration.

2. A composition of claim 1 which is a tablet.

3. A composition of claim 1 wherein the composition is in the form of a capsule.

4. A composition of claim 1 wherein the composition is a liquid.

5. A sterile composition of matter comprising a tumor proliferation inhibiting effective amount of α AED or an ester or ether thereof of the formula:




wherein R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR₂, wherein R₂ is H; alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or phenyl, and any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, in a sterile solution appropriate for parenteral administration.

6. A composition of claim 5 in single dosage form in a container.

7. A composition of claim 5 in an isotonic solution.

8. A composition of claim 5 containing the α AED in a cyclodextrin inclusion complex.

9. A composition of matter comprising a tumor proliferation inhibiting effective amount of α AED or a compound of the formula:




wherein either R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR₂, wherein R₂ is H; alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or phenyl, and any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, on a solid support.

10. A composition of claim 9 which is a patch for application to the skin.

11. A composition of claim 9 which is a sponge.

12. A composition of matter comprising a tumor proliferation inhibiting effective amount of a compound of the formula:



wherein either R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR₂, wherein R₂ is H; alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or phenyl, and any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain,

branched chain, or the alkyl may be wholly or partially cyclized, in a pharmaceutically acceptable carrier wherein said composition contains, additionally, as an active agent, a second anti-cancer drug.

5

13. A composition of claim 12 wherein the second anti-cancer drug is a antiandrogen or antiestrogen.

10

14. A composition of claim 12 wherein the second anticancer drug is a urea.

15. A composition of claim 12 wherein the second anticancer drug is an alkylating agent.

15

16. A composition of claim 12 wherein the second anticancer drug is an antimetabolite.

20

17. A composition of matter wherein the second anticancer drug is a DNA intercalating agent.

18. A composition of claim 12 wherein the second anticancer drug is an interferon.

25

19. A composition of claim 12 wherein the second anticancer drug is a nucleic acid inhibitor.

20. A composition of claim 12 wherein the second anticancer drug is a vinca alkaloid.


30

21. A composition of claim 21 wherein the second anticancer drug is RU486. composition of claim 1.

35

22. A method of accerlerating cell aging and programed cell death by administering a composition containing a cell agging accelerating effective amount of a compound of the formula:

5



10

15

20

wherein either R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR₂, wherein R₂ is H; alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or phenyl, and any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, in a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/05849

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/56

US CL : 514/171; 182

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/171; 182

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

USCL 524/271, 182

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A, 5,206,008 (LORIA) 27 April 1993, see entire document.	1-21
Y	US,A, 5,478,566 (LORIA) 26 December 1995, see entire document.	1-21

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

20 MAY 1997

Date of mailing of the international search report

08 JUL 1997

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JEROME D. GOLDBERG

Telephone No. (703) 308-1235